Zombie Aqua™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
1-Zombie_Aqua_Viability_Dye_nowash_050713
One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • 1-Zombie_Aqua_Viability_Dye_nowash_050713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • b-Zombie_Aqua_Viability_Dye_032713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • c-Zombie_Aqua_Viability_Dye_012721
    HeLa cells were treated with 20% EtOH for 20 seconds, washed twice with PBS, and then were left to recover for five minutes with cell culture media in 37°C. The cells were stained with Zombie Aqua™ (1:1000) (cyan) for 15 minutes and then fixed with 1% paraformaldehyde (PFA) for ten minutes. Nuclei were counterstained with DRAQ5 (Red) for five minutes. The image was captured with 40X objective.
See Zombie Aqua™ spectral data
Cat # Size Price Quantity Check Availability Save
423101 100 tests £61
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423102 500 tests £230
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Aqua™ is a polar, water-soluble dye providing very bright green fluorescence, making it suitable for use in multi-color detection.
 

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie Aqua™ Fixable Viability Kit is composed of lyophilized Zombie Aqua™ dye and anhydrous DMSO. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved. 100 tests = 1 vial of Zombie Aqua™ + DMSO, 500 tests = 5 vials of Zombie Aqua™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Aqua™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC, ICFC - Quality tested
ICC - Verified

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunofluorescence microscopy, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

 

Excitation Laser
Violet Laser (405 nm)
Application Notes

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Aqua™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µl Zombie Aqua™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µl for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  5. Incubate the cells at room temperature, in the dark, for 15-30 minutes.
  6. Wash one time with 2 ml BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

 

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully  dissolved
  3. Determine the total µl volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µl. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Aqua™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µl of antibody cocktail for a 100 µl total staining volume, use 80 µl of Zombie Aqua™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Aqua™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.

    Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.

  4. Incubate for 10-15 minutes at RT, protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.


Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Aqua™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Aqua™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Aqua™.

Zombie Aqua™ dye is excited by the violet laser and has a maximum emission of 516 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Aqua™ dye has similar emission to Brilliant Violet 510™.

Additional Product Notes

View more applications data using this product to validate Veri-Cells™ lyophilized control cells and to study dendritic cell subsets.

Application References

(PubMed link indicates BioLegend citation)
  1. Vom Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  2. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  3. Price PJ, et al. 2014. J Virol. 88:10840. PubMed
  4. Schmid MA, et al. 2014. PLoS Pathog. 10:1004541. PubMed
  5. Cohen SB, et al. 2015. J Immunol. 194:210. PubMed
  6. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  7. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  8. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  9. Tzeng A, et al. 2015. PNAS. 112:3320. PubMed
  10. Peres AG, et al. 2015. Infect Immun. 83:1587. PubMed
  11. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
Product Citations
  1. Bussières-Marmen S, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.72. PubMed
  2. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  3. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  4. Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed
  5. Tasker C, et al. 2021. AAPS J. 23:26. PubMed
  6. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  7. Kim J, et al. 2021. Front Cell Neurosci. 638098:15. PubMed
  8. Nuccitelli R, et al. 2017. J Immunother Cancer . 10.1186/s40425-017-0234-5. PubMed
  9. Kaczanowska S, et al. 2017. Cancer Res. . 10.1158/0008-5472.CAN-17-0653. PubMed
  10. Gálvez-Cancino F, et al. 2018. Oncoimmunology. 7:e1442163. PubMed
  11. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  12. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  13. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  14. Rueschenbaum S, et al. 2021. Front Immunol. 11:581352. PubMed
  15. Fantone K, et al. 2021. Pathogens. 10:. PubMed
  16. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  17. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  18. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  19. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  20. Castle AR, et al. 2022. PLoS One. 17:e0269342. PubMed
  21. Healy LM, et al. 2020. Glia. 68:811. PubMed
  22. Buchanan MW, et al. 2021. J Orthop Res. 39:1710. PubMed
  23. Seki SM, et al. 2020. Sci Signal. :13. PubMed
  24. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  25. Fujii H, et al. 2015. PLoS One. 10: 0133216. PubMed
  26. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  27. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  28. Böttcher M, et al. 2018. Oncoimmunology. 7:e1445454. PubMed
  29. Jeevan-Raj B, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.071. PubMed
  30. Lam B, et al. 2021. Cell Rep. 37:109838. PubMed
  31. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  32. Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed
  33. Volta V, et al. 2021. Nat Commun. 12:6979. PubMed
  34. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  35. Price P, et al. 2014. J Virol. 88:10840. PubMed
  36. Tzeng A, et al. 2015. Proc Natl Acad Sci U S A. 112:3320. PubMed
  37. Yamaguchi M, et al. 2016. J Leukoc Biol. 100: 131 - 141. PubMed
  38. Swee L, et al. 2016. Open Bio. 6: 160293. PubMed
  39. Lownik JC, et al. 2020. Biochem Biophys Res Commun. 522:442. PubMed
  40. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  41. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  42. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  43. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  44. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  45. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  46. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  47. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  48. Shin HS, et al. 2022. Sci Rep. 12:17605. PubMed
  49. Meyer Zu Natrup C, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  50. Toomer G, et al. 2022. Viruses. 14:. PubMed
  51. Li LH, et al. 2020. Antiviral Res. 104929:183. PubMed
  52. Jenull S, et al. 2021. Cell Reports. 36(3):109406. PubMed
  53. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  54. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  55. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  56. Alberts-Grill N, et al. 2016. J Immunol. 197(12):4651-4662. PubMed
  57. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  58. Torre S, et al. 2016. Nat Immunol. 10.1038/ni.3581. PubMed
  59. Bittner-Eddy P, et al. 2016. J Immunol. 197: 1435 - 1446. PubMed
  60. Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  61. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  62. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  63. Hartsough EJ, et al. 2019. Cell Death Dis. 10:281. PubMed
  64. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
  65. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  66. Setten E, et al. 2022. Nat Commun. 13:6499. PubMed
  67. Liu Y, et al. 2022. Cancer Discov. :. PubMed
  68. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  69. Munoz MA, et al. 2021. Elife. 10:. PubMed
  70. Gong W, et al. 2021. Oncoimmunology. 10:1997385. PubMed
  71. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  72. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  73. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  74. Witkowski M, et al. 2021. Nature. 600:295. PubMed
  75. Deng X, et al. 2021. Open Biol. 11:200340. PubMed
  76. Yu X, et al. 2021. Nature. 594:560. PubMed
  77. Park JJ, et al. 2021. Nat Commun. 12:1222. PubMed
  78. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  79. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  80. Peres A, et al. 2015. Infect Immun . 83:1587. PubMed
  81. Yoshida N, et al. 2016. Nat Commun. 7: 12993. PubMed
  82. Fang V, et al. 2016. Nat Immunol. 18:15-25. PubMed
  83. Hagen SH, et al. 2020. Cell Rep. 33:108485. PubMed
  84. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  85. Wright AKA, et al. 2017. J Allergy Clin Immunol. 140:1430. PubMed
  86. Botuyan MV, et al. 2018. Nat Struct Mol Biol. 25:591. PubMed
  87. Darzianiazizi M, et al. 2021. Cytokine X. 3:100053. PubMed
  88. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  89. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  90. Pedersen JG, et al. 2021. Front Microbiol. 12:763030. PubMed
  91. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  92. Bresque M, et al. 2022. J Biol Chem. :101711. PubMed
  93. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  94. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  95. Ruetsche D, et al. 2022. Cells. 11:. PubMed
  96. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  97. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  98. Amberg N, et al. 2016. J Invest Dermatol. 136:2140-2149. PubMed
  99. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  100. Schmitt N, et al. 2015. Mol Cancer Ther. 14: 2103-2111. PubMed
  101. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  102. Grozio A, et al. 2019. Nat Metab. 1:47. PubMed
  103. Ramsey HE, et al. 2018. Cancer Discov. 8:1566. PubMed
  104. Parameswaran P, et al. 2017. Cell Host Microbe. 10.1016/j.chom.2017.08.003. PubMed
  105. Chen Z, et al. 2022. Theranostics. 12:6242. PubMed
  106. Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed
  107. Luo X, et al. 2021. J Biol Chem. 297:101098. PubMed
  108. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  109. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  110. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  111. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  112. Denkers S 2015. J Immunol. 195: 2754-2762. PubMed
  113. Garcia-Bates T, et al. 2016. J Immunol. 196: 2870 - 2878. PubMed
  114. Davidson S, et al. 2016. EMBO Mol Med. 8: 1099 - 1112. PubMed
  115. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  116. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  117. Jordan PM, et al. 2020. Cell Rep. 33:108247. PubMed
  118. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  119. Dillon SM, et al. 2020. Bio Protoc. e3486:10. PubMed
  120. Pantelyushin S, et al. 2021. Cancers (Basel). :13. PubMed
  121. Ceholski D, et al. 2017. Stem Cell Res. 10.1016/j.scr.2017.06.015. PubMed
  122. Metzemaekers M, et al. 2017. Int J Mol Sci. 10.3390/ijms18071513. PubMed
  123. Tien S, et al. 2017. PLoS One. 10.1371/journal.pone.0181338. PubMed
  124. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  125. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  126. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  127. Stuani L, et al. 2021. J Exp Med. 218:. PubMed
  128. Zheng S, et al. 2022. Blood Cancer Discov. 3:103. PubMed
  129. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  130. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  131. Tang Y, et al. 2021. Cancer Discov. 11:3142. PubMed
  132. Borst L, et al. 2022. Int J Cancer. 150:688. PubMed
  133. Alvisi G, et al. 2022. Methods Mol Biol. 2559:243. PubMed
  134. Li FJ, et al. 2022. PLoS One. 17:e0277019. PubMed
  135. Audiger C, et al. 2020. J Immunol. 205:121. PubMed
  136. Fernandez-Castaneda A, et al. 2020. Acta Neuropathol. 139:365. PubMed
  137. Köchl R, et al. 2020. Elife. 9:00. PubMed
  138. Honarpisheh P, et al. 2020. J Neuroinflammation. 0.9625. PubMed
  139. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  140. Crisci E, et al. 2016. J Virol. 90: 4939 - 4950. PubMed
  141. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
  142. Chakraborty A, et al. 2020. Cell Rep. 32:108179. PubMed
  143. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  144. Kruse S, et al. 2018. Oncoimmunology. 8:e1524694. PubMed
  145. Louveau A, et al. 2018. Curr Protoc Immunol. 121:1. PubMed
  146. Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed
  147. Joshi N and Werner S. 2017. PLoS One. 10.1371/journal.pone.0187162. PubMed
  148. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  149. Wang Z, et al. 2022. Nat Commun. 13:5447. PubMed
  150. Romine KA, et al. 2021. Blood Cancer Discov. 2:518. PubMed
  151. Romine KA, et al. 2021. Cancer Discov. . PubMed
  152. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  153. Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
  154. Karagianni AE, et al. 2021. Sci Rep. 11:14292. PubMed
  155. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  156. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  157. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  158. Yang Y, et al. 2016. Nucleic Acids Res. 44: 4174 - 4188. PubMed
  159. Coria L, et al. 2016. J Immunol. 196: 4014 - 4029. PubMed
  160. Zhang F, et al. 2020. EMBO Mol Med. e12034:12. PubMed
  161. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  162. Rechtien A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.08.023. PubMed
  163. Yamazaki T, et al. 2020. Oncoimmunology. 9:1721810. PubMed
  164. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  165. Xing J, et al. 2021. Nat Commun. 12:2681. PubMed
  166. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  167. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  168. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  169. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  170. Hu H, et al. 2021. Cancer Immunol Res. 9:1298. PubMed
  171. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  172. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
  173. Tsang M, et al. 2020. Am J Pathol. 190:206. PubMed
  174. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  175. Brugat T, et al. 2017. Nat Microbiol. 2:16276. PubMed
  176. Andriessen E, et al. 2016. EMBO Mol Med. 8(12):1366-1379. PubMed
  177. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  178. Krämer B, et al. 2016. PLoS One. 11: 0162068. PubMed
  179. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  180. Contreras F, et al. 2016. J Immunol. 196: 4143 - 4149. PubMed
  181. Larmonier C, et al. 2016. J Biol Chem. 291: 8918-8930. PubMed
  182. Lim X, et al. 2016. Proc Natl Acad Sci U S A. 113: 1498 - 1505. PubMed
  183. Carmona SJ, et al. 2020. Oncoimmunology. 9:1737369. PubMed
  184. Haloul M, et al. 2019. Sci Rep. 9:14050. PubMed
  185. Engelbertsen D, et al. 2019. Sci Rep. 9:10608. PubMed
  186. Freire DM, et al. 2019. Mol Cell. 73:1282. PubMed
  187. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  188. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  189. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  190. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  191. Shen J, et al. 2022. Front Immunol. 13:762580. PubMed
  192. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  193. Cohen S, et al. 2015. J Immunol. 194:210. PubMed
  194. Price P, et al. 2015. J Immunol. 194:1164. PubMed
  195. Chattopadhyay A, et al. 2016. J Lipid Res. 57: 832 - 847. PubMed
  196. Dutzan N, et al. 2017. Immunity. 46(1):133-147. PubMed
  197. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  198. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  199. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  200. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  201. Fragniere AMC, et al. 2019. Sci Rep. 9:2288. PubMed
  202. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  203. Neal JT, et al. 2018. Cell. 175:1972. PubMed
  204. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  205. Zebertavage LK, et al. 2020. Sci Rep. 10:7376. PubMed
  206. Sabree SA, et al. 2021. J Immunother Cancer. 9: . PubMed
  207. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  208. Pan W, et al. 2021. J Immunol. 206:1719. PubMed
  209. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  210. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  211. Bankova AK, et al. 2022. Transplant Cell Ther. . PubMed
  212. Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed
  213. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  214. Rossignol J, et al. 2022. iScience. 25:104353. PubMed
  215. Karagianni A, et al. 2022. Front Oncol. 12:929498. PubMed
  216. Castro JT, et al. 2022. Nat Commun. 13:4831. PubMed
  217. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  218. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  219. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  220. Wang L, et al. 2020. EMBO J. 39:e104514. PubMed
  221. Ryan P, et al. 2016. Proc Natl Acad Sci U S A. 113(50):14378-14383. PubMed
  222. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  223. Tron AE, et al. 2018. Nat Commun. 9:5341. PubMed
  224. Collin R, et al. 2017. J Immunol. 10.4049/jimmunol.1600789. PubMed
  225. Teng Y, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0485-0. PubMed
  226. Huo Y, et al. 2022. Front Immunol. 13:983116. PubMed
  227. Clark GC, et al. 2022. Front Oncol. 12:913656. PubMed
  228. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  229. Rocha-Resende C, et al. 2021. J Mol Cell Cardiol. 157:98. PubMed
  230. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  231. Barington L, et al. 2022. Cells. 11:. PubMed
  232. Bendtsen SK, et al. 2022. Oncoimmunology. 11:2026020. PubMed
  233. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  234. Huo Y, et al. 2021. BMC Genomics. 22:145. PubMed
  235. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  236. Schmid M, Harris E 2014. PLoS Pathog. 10:1004541. PubMed
  237. Yoder A, et al. 2017. PLoS Pathog. 13(2):e1006226. PubMed
  238. Davey M, et al. 2017. Nat Commun. 10.1038/ncomms14760. PubMed
  239. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  240. Hagen SH, et al. 2021. STAR Protocols. 2(3):100641. PubMed
  241. Madsen D, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.12.011. PubMed
  242. Becker JR, et al. 2018. Nat Commun. 9:5406. PubMed
  243. Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed
  244. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  245. Santos NB, et al. 2021. PLoS Pathog. 17:e1009381. PubMed
  246. Miller JE, et al. 2021. JCI Insight. 6:. PubMed
  247. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  248. Lee GJ, et al. 2022. Oncoimmunology. 11:2015170. PubMed
  249. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  250. Shibata H, et al. 2021. Oncoimmunology. 10:1958589. PubMed
  251. Constant DA, et al. 2022. Immunohorizons. 6:416. PubMed
  252. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  253. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  254. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  255. Concha-Benavente F, et al. 2016. Cancer Res . 76: 1031 - 1043. PubMed
  256. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  257. Ogrinc Wagner A, et al. 2019. PLoS One. 14:e0210998. PubMed
  258. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  259. Li H, et al. 2022. Front Immunol. 13:946202. PubMed
  260. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  261. McCallion A, et al. 2022. Front Immunol. 13:961599. PubMed
  262. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  263. Alice AF, et al. 2021. Sci Rep. 11:16347. PubMed
  264. Singh AK, et al. 2022. Nat Commun. 13:878. PubMed
  265. Kumar S, et al. 2022. Gut. . PubMed
  266. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  267. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  268. Nylund P, et al. 2021. Cell Death Dis. 12:167. PubMed
  269. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  270. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  271. de Winde CM, et al. 2021. J Cell Sci. 134: . PubMed
  272. Leong Y, et al. 2016. Nat Immunol. 17:1187-1196. PubMed
  273. Ohs I, et al. 2016. Nat Commun. 7:13708. PubMed
  274. Schuldt N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1700406. PubMed
  275. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  276. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  277. Vigeland CL, et al. 2019. Physiol Rep. 7:e14019. PubMed
  278. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  279. Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
  280. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  281. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  282. Wegrecki M, et al. 2022. Nat Commun. 13:3872. PubMed
  283. Peng Z, et al. 2022. J Neuroinflammation. 19:186. PubMed
  284. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  285. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  286. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  287. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  288. Luo X, et al. 2020. J Clin Invest. 130:1635. PubMed
  289. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  290. Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed
  291. Ju X, et al. 2016. J Immunol. 197(12):4613-4625. PubMed
  292. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  293. Gouwy M, et al. 2016. PLoS One. 11:e0166006. PubMed
  294. McGuire V, et al. 2016. Sci Rep. 6:31159. PubMed
  295. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  296. Carpenter S, et al. 2016. PLoS Pathog. 12: 1005380. PubMed
  297. Jerby–Arnon L, et al. 2018. Cell. 175:984. PubMed
  298. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  299. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  300. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  301. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  302. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  303. Li M, et al. 2021. Mol Biomed. 2:41. PubMed
  304. Milich LM, et al. 2021. J Exp Med. 218:. PubMed
  305. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  306. Fucà G, et al. 2021. J Immunother Cancer. 9:. PubMed
  307. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  308. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  309. Martini E, et al. 2016. Cell Rep. 14:1062-1073. PubMed
  310. Weiss G, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.104. PubMed
  311. Neidleman J, et al. 2017. PLoS Pathog. 13(2):e1006163. PubMed
  312. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  313. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  314. Blair TC, et al. 2020. J Immunol. 204:3416. PubMed
  315. Dhimolea E, et al. 2021. Cancer Cell. 39:240. PubMed
  316. Li Y, et al. 2022. Theranostics. 12:5364. PubMed
  317. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  318. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  319. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  320. Salahudeen AA, et al. 2020. bioRxiv. . PubMed
  321. Farooq F, et al. 2016. Sci Rep. 6:27944. PubMed
  322. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  323. Tomlinson JE, et al. 2018. J Neuroinflammation. 0.753472222. PubMed
  324. Padhye A, et al. 2019. Sci Rep. 9:4819. PubMed
  325. Yuan C, et al. 2018. iScience. 11:13. PubMed
  326. Tiberti S, et al. 2022. Nat Commun. 13:6752. PubMed
  327. Bozoglu T, et al. 2022. Adv Sci (Weinh). 9:e2103867. PubMed
  328. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  329. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  330. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  331. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  332. Verma M, et al. 2021. J Exp Med. 218:. PubMed
  333. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  334. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  335. Krogmann A, et al. 2016. PLoS One. 11: 0146326. PubMed
  336. Johns S, et al. 2016. Circ Res . 119: 210 - 221. PubMed
  337. Cho SX, et al. 2020. Nat Commun. 4.481944444. PubMed
  338. Filippo Buono M, et al. 2020. Cells. 9:00. PubMed
  339. Dai H, et al. 2017. J Immunol. 10.4049/jimmunol.1700418. PubMed
  340. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  341. Friedrich V, et al. 2021. Gut Microbes. 13:1. PubMed
  342. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  343. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  344. Schaller MA, et al. 2021. JCI Insight. 6:e148003. PubMed
  345. Pan L, et al. 2021. Stem Cell Res Ther. 12:496. PubMed
  346. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  347. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  348. Spath S, et al. 2022. iScience. 25:104998. PubMed
  349. Schreurs RRCE, et al. 2021. Mucosal Immunology. 14(3):605-614. PubMed
  350. Workel HH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  351. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  352. Salahudeen AA, et al. 2020. Nature. 588:670. PubMed
  353. Hatfield J, Brown M 2015. Cell Immunol. . PubMed
  354. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  355. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  356. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  357. Kimura K, et al. 2018. Nat Commun. 9:17. PubMed
  358. Wang CJH, et al. 2022. J Biol Chem. :102714. PubMed
  359. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  360. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  361. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed
  362. Khurana P, et al. 2021. Front Immunol. 12:700374. PubMed
  363. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  364. Chakraborty A, et al. 2021. Biomaterials. 273:120796. PubMed
  365. Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed
  366. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  367. Tee YC, et al. 2021. FASEB Bioadv. 3:829. PubMed
  368. Xia L, et al. 2021. Cancer Immunol Res. 9:707. PubMed
  369. Chiou SH, et al. 2021. Immunity. 54:586. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

Is Zombie Aqua™ an equivalent to cell labeling and tracer dyes such as CellTrace™ Violet and CFSE?

Zombie Aqua™ is not a direct equivalent to such dyes because their mechanism of action and scope of application are entirely different.

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

Can I use the UV laser to stimulate Zombie Aqua™? If so, can I then use it in conjunction with BV510™?

While we typically do not test Zombie Aqua™ with the UV laser, its excitation peak suggests it is effectively excited at 355 nm. However, we would not recommend using BV510™ off the violet laser and Zombie Aqua™ off the UV laser at the same time. Due to cross-beam excitation of BV510™ by the UV laser and the violet excitation of Zombie Aqua™, this would lead to significantly increased background and excessive compensation requirements.


How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 8    Revision Date: 01/27/2021

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account